Page 95 - Mployee Wellness Programs News Today

Here is a selection of recent executive hires, promotions and layoffs occurring across the healthcare industry.

As the debate over worker misclassification rages, it's important that healthcare professionals know the facts. Staffing agencies that designate their nurses as independent contractors avoid the costs of employment-related benefits like insurance, workers’ compensation, and overtime pay. These agencies also lack necessary clinical and professional oversight over their contractors, which increases the risk of substandard care.

Although many employers and consumers don't understand the difference between value-based care and fee-for-service, most are in favor of value-based care after being given the definition, a new survey found.

Team-based primary care is needed now more than ever as our “on-demand” and mobile lives, complicated by a primary care shortage crisis, have led to a more transactional and fragmented healthcare experience.

Bristol Myers Squibb drug Reblozyl is now approved as a first-line therapy for anemia caused by myelodysplastic syndromes, a group of blood cancers. It’s the third indication for the drug, which analysts project could top $4 billion in peak sales.

We must advocate for the positive impact that technology can have on healthcare outcomes, while also building solutions to create a more equitable health system. This includes traditional, less tech-reliant methods for those unable to embrace technology.

Luna — an at-home physical therapy provider — released a new study on the efficacy of its post-surgery rehabilitation program. The study, which was conducted by the startup, showed that the Luna Pathways program did a good job of reducing patients’ pain, increasing care plan adherence, and decreasing avoidable hospital readmissions and emergency department visits.

The Apellis Pharmaceuticals restructuring will save up to $300 million. It comes as the biotech continues its inquiry into the cause of a rare inflammatory complication reported in a small number of patients who received its geographic atrophy drug, Syfovre.

HHS released the first 10 drugs selected for the Medicare Drug Price Negotiation Program. These drugs include Eliquis, Jardiance and Xarelto. Under the program, the federal government will be able to negotiate the price for selected drugs for the first time.

Even with my “VIP” access to the healthcare system as a physician who practiced in my community, I’m still struggling to coordinate my care as a cancer patient. I believe patients need more from their payers, providers, and digital health collaborators when it comes to care coordination and navigation.